What is PHAR's P/E ratio?

Pharming Group NV (PHAR) currently trades at a P/E ratio of 49.25.

Pharming Group NV reports a Return on Equity (ROE) of 3.43%.

What is PHAR's dividend yield?

Pharming Group NV offers a dividend yield of 0.00%.

What is PHAR's Quality Score?

Our AI rates PHAR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PHAR?

Our AI Timing Score for PHAR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PHAR belong to?

Pharming Group NV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Pharming Group NV (PHAR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-06-30)

PHAR AI Analysis Summary

Our AI summary for PHAR: Pharming Group NV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 49.25, ROE of 3.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PHAR

Pharming Group NV

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 9.82

-0.26 (-2.58%) Day Change

Watchlist Portfolio Compare Chart

49.25

P/E

0.38

D/E

3.4%

ROE

2.0%

ROA

0.00%

Div Yield

-0.48

PEG

PHARMING GROUP NV
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 9.82 Price -0.26 (-2.58%) Day Change	NEWS SCORE: 97

PHAR, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	2979
Magic Formula Rank by ROE	2979
Magic Formula Rank by ROIC	2388
Price	9.82
PBV / Sector	2.64 / 44,219.29
Earning Per Share	0.13

PE / Sector	49.25 / 19.28
PEG or PE/Growth / Sector	-0.48 / 1.23
Average 1M Daily Value	0.12 M GREAT
Average 1W Daily Value	0.24 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	2.53 / 98.22
NPM Average (%) / Sector	0.33 / -1,697.63
NPM Change Average (%) / Sector	-14.29 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	1.98 / 185,260.96
ROA Average (%) / Sector	0.10 / 36,684.70
ROA Change Average (%) / Sector	-3.24 / 422,221.66
ROE (%) / Sector	3.43 / 243,762.23
ROE Average (%) / Sector	0.19 / 48,758.47
ROE Change Average (%) / Sector	-11.79 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:02:00
Symbol	PHAR
Name	PHARMING GROUP NV
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	70.78 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	713.44 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Darwinweg 24, Leiden, Netherlands, 2333 CR

Phone: 31 71 524 7400

Website: https://www.pharming.com

Employees: 407

Sector: Healthcare >> Biotechnology

Description: Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.